Tumor NGS Genetic Testing Market, Global Outlook and Forecast 2024-2030
The global Tumor NGS Genetic Testing market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Liquid Biopsy (Blood Sample) Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Tumor NGS Genetic Testing include Foundation Medicine, Guardant Health, Illumina, Thermo Fisher Scientific Inc., DIAN DIAGNOSTICS Group Co., Ltd., Burning Rock Biotech., NovogeneCo.,Ltd., Nanjing Shihejiyin Technology, Inc. and Amoy Diagnostics Co.,Ltd., etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Tumor NGS Genetic Testing is to use high-throughput sequencing to understand tumors at the genetic level, detect and quantify the genetic components that drive tumors.
This report aims to provide a comprehensive presentation of the global market for Tumor NGS Genetic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor NGS Genetic Testing. This report contains market size and forecasts of Tumor NGS Genetic Testing in global, including the following market information:
Global Tumor NGS Genetic Testing Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the Tumor NGS Genetic Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tumor NGS Genetic Testing Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Tumor NGS Genetic Testing Market Segment Percentages, by Type, 2023 (%)
Liquid Biopsy (Blood Sample)
Tissue Biopsy
Global Tumor NGS Genetic Testing Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Tumor NGS Genetic Testing Market Segment Percentages, by Application, 2023 (%)
Companion Diagnostics
Early Cancer Screening
Drug Discovery
Global Tumor NGS Genetic Testing Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Tumor NGS Genetic Testing Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tumor NGS Genetic Testing revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Tumor NGS Genetic Testing revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Foundation Medicine
Guardant Health
Illumina
Thermo Fisher Scientific Inc.
DIAN DIAGNOSTICS Group Co., Ltd.
Burning Rock Biotech.
NovogeneCo.,Ltd.
Nanjing Shihejiyin Technology, Inc.
Amoy Diagnostics Co.,Ltd.
China National Pharmaceutical Group Corporation
Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.
Guangzhou Kingmed Diagnostics Group Co.,Ltd.
ADICON Clinical Laboratories, Inc.
Genetron
Genecast Group Inc.
BGI Genomics Co.,Ltd.
Beijing-Geneplus Technology Limited.
Xiamen SpacegenCo., Ltd.
Geneis?Beijing?Co.Ltd.
HaploX
Outline of Major Chapters:
Chapter 1: Introduces the definition of Tumor NGS Genetic Testing, market overview.
Chapter 2: Global Tumor NGS Genetic Testing market size in revenue.
Chapter 3: Detailed analysis of Tumor NGS Genetic Testing company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Tumor NGS Genetic Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
